Developer docs
API playgroundTry for free, no card

Search company profiles

Synthekine

Full company profile

uuid0000msk

Namestring
Synthekine
Legal namestring
Synthekine, Inc.
Websiteurl
synthekine.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Synthekine is a private, clinical-stage biotherapeutics company founded in 2018 and headquartered in Menlo Park, California, that engineers next-generation cytokine therapeutics for oncology and autoimmune/inflammatory diseases. The company deploys three proprietary cytokine engineering platforms: Cytokine Partial Agonists (which tune receptor binding to decouple efficacy from toxicity), Orthogonal IL-2 (orthoIL-2) Technology (which creates engineered ligand-receptor pairs independent of the endogenous cytokine system to enable controlled in vivo expansion of cell therapies), and Surrogate Cytokine Agonists (SCAs) (which dimerize or multimerize receptor subunits in non-natural configurations to create novel cell selectivity). The lead clinical asset STK-012, an α/β-biased IL-2 partial agonist, is in a global randomized Phase 2 trial (SYNERGY-101) in first-line PD-L1 negative nonsquamous NSCLC and has generated a 50% Phase 1b response rate versus 23-32% for standard treatments; SYNCAR-001 combined with STK-009 (orthogonal IL-2 plus CD19 CAR-T) received FDA Fast Track Designation for lupus without lymphodepletion.

Synthekine operates as a pre-revenue clinical-stage biotech with no commercialized products and derives its capital base from equity financings — $82M Series A (2020), $107.5M Series B (2021), and $100M Series C (2023), totaling approximately $313M from investors including Canaan Partners, Samsara BioCapital, The Column Group, Deerfield Management, and Janus Henderson Investors. The go-to-market model combines internal pipeline development with strategic pharma collaborations: a 2021 worldwide research and licensing agreement with Merck leveraging the SCA platform, a January 2024 strategic collaboration with Sanofi on selective IL-10 receptor agonists for inflammatory disease, and a February 2026 clinical trial collaboration with Merck to evaluate STK-012 plus Keytruda in the SYNERGY-101 study. Future revenue mechanics depend on partnership upfronts, milestone payments, and royalties rather than direct sales.

The company serves patients in oncology (solid tumors including NSCLC, hepatocellular carcinoma; CD19+ hematologic malignancies) and autoimmune/inflammatory disease (systemic lupus erythematosus and related conditions), with scientific leadership grounded in founder K. Christopher Garcia's Stanford structural biology research, CMO Naiyer Rizvi's checkpoint immunotherapy track record, and a board that includes the scientific leads behind ipilimumab and nivolumab discovery. Synthekine retains worldwide rights to its core programs and employs 51-100 people across its single Menlo Park headquarters.

Short descriptiontext

Synthekine is a pre-revenue, clinical-stage biotherapeutics company engineering selective cytokine therapeutics via three platforms — Cytokine Partial Agonists, Orthogonal IL-2, and Surrogate Cytokine Agonists — for oncology and autoimmune diseases, with lead asset STK-012 in Phase 2 for NSCLC.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
engineered cytokine therapeutics, cytokine partial agonists, orthogonal IL-2 therapeutics, immuno-oncology biopharmaceuticals, CAR-T combination therapies
Industry5 codes
PRIMARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cytokine Therapeutics / Biopharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Revenue
TypeLicensing Royalties
Description

Pre-revenue clinical stage biotech company. Revenue expected from commercialization of cytokine therapeutic pipeline including STK-012 (Phase 2), STK-026 (IND enabling), and cell therapy programs. Partnerships with Merck and Sanofi provide upfront payments and potential milestone payments plus royalties.

synthekine.com
2Strategic Collaboration Payments
TypeLicensing Royalties
Description

Collaboration agreements with pharmaceutical partners generate upfront payments, research funding, development milestones, and commercial royalties. Examples include Sanofi IL-10 collaboration and Merck surrogate cytokine agonist platform partnership.

synthekine.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Synthekine discovers, develops and plans to commercialize engineered cytokine therapeutic candidates for cancer and autoimmune, inflammatory, and metabolic diseases. Its lead clinical programs include STK-012 (IL-2 partial agonist in Phase 2 for non-small cell lung cancer), STK-009 + SYNCAR-001 (orthogonal IL-2 paired with CD19 CAR-T, FDA Fast Track designated for lupus), and STK-026 (IL-12 partial agonist). The company monetizes its pipeline through a mix of internal development, co-development partnerships (Merck, Sanofi) and milestone/royalty-bearing licensing agreements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 50% response rate with STK-012 in PD-L1 negative NSCLC vs 23-32% with standard treatments
+1 more record
Product and service5 records
1STK-012
CategoryOncology therapeutic candidate
Description

STK-012 is an α/β-biased IL-2 partial agonist designed to preferentially stimulate tumor-killing T cells while avoiding toxicity from NK cells and naïve T cells. It is in Phase 2 (SYNERGY-101) for first-line PD-L1 negative non-squamous NSCLC, with Phase 1b data showing a 50% response rate vs. 23-32% with standard treatments in this population.

2STK-009 + SYNCAR-001 (CD19 CAR-T combination)
CategoryCell therapy combination candidate
Description

Combination of STK-009, an orthogonal IL-2 ligand, with SYNCAR-001, a CD19 CAR-T cell therapy engineered to express the orthogonal IL-2 receptor. Designed to deliver highly selective proliferation and activation in vivo, removing the need for lymphodepletion and increasing durability and potency of adoptive cell therapies. Indication targets include CD19+ hematologic malignancies and lupus.

3STK-026
CategoryOncology therapeutic candidate
Description

STK-026 is a detoxified IL-12 partial agonist designed to sustain CD8+ T cell activity while reducing NK-mediated cytokine release and toxicities associated with wild-type IL-12. Program is in IND-enabling development.

4Selective IL-10 receptor agonist program (Sanofi collaboration)
CategoryInflammation / autoimmune therapeutic candidate
Description

Selective IL-10 receptor agonists developed through Synthekine's cytokine partial agonist platform for the treatment of inflammatory and autoimmune diseases. Licensed to Sanofi under a strategic collaboration; Synthekine performs research through preclinical stage, after which Sanofi assumes preclinical, clinical, and commercial responsibility.

5Surrogate Cytokine Agonists (SCA) platform program (Merck collaboration)
CategoryLicensed cytokine platform program
Description

Surrogate Cytokine Agonists developed using Synthekine's SCA platform, which dimerizes or multimerizes cytokine receptor subunits in ways wild-type cytokines cannot, enabling non-natural receptor pairing. Licensed to Merck for up to two cytokine targets, with Synthekine performing initial research and Merck holding exclusive development, manufacturing and commercialization rights.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-26
Description

Clinical trial collaboration and supply agreement to evaluate STK-012 in combination with Keytruda (pembrolizumab) and chemotherapy in the SYNERGY-101 randomized Phase 2 study for first-line PD-L1 negative nonsquamous NSCLC. Merck supplies Keytruda for the combination regimen. Both companies retain commercial rights to their respective compounds as monotherapies or in combination regimens.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-25
Description

Strategic collaboration to develop and commercialize selective IL-10 receptor agonists for the treatment of inflammatory diseases. Collaboration focuses on advancing Synthekine's multiple approaches to optimizing IL-10. Synthekine and Sanofi collaborate on research activities up to a defined point of preclinical development, after which Sanofi assumes responsibility for preclinical, clinical, and commercial activities.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-11-01
Description

Worldwide research collaboration and licensing agreement leveraging Synthekine's proprietary surrogate cytokine agonist platform to discover, develop and commercialize novel cytokine therapeutics. Synthekine responsible for initial research efforts in collaboration with Merck, and Merck has exclusive rights to develop, manufacture and commercialize surrogate cytokine agonists for up to two cytokine targets.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech with tumor-activated immunotherapies including engineered cytokines and immune cell engagers. Competes in the same immuno-oncology and cytokine-engineering space as Synthekine, with a focus on selective activation in the tumor microenvironment.

TypeEmerging player
Description

Clinical-stage allogeneic CAR-T developer with a broad pipeline of off-the-shelf cell therapies. Comparable to Synthekine's SYNCAR-001 + STK-009 CAR-T + orthogonal IL-2 program as it advances into autoimmune indications like lupus without lymphodepletion.

TypeEmerging player
Description

Clinical-stage biotech developing engineered IL-2 and IL-15 cytokine variants (e.g., CUG252) for autoimmune disease. Directly comparable to Synthekine's engineered cytokine efforts in inflammation/autoimmune indications.

TypeDirect peer
Description

Clinical-stage biotech developing PREDATOR platform-engineered cytokine therapeutics (INDUKINEs) for oncology. Most direct comparable to Synthekine's engineered-cytokine approach and selective IL-2/IL-12 partial agonism, with multiple programs in clinical development for solid tumors.

TypeBroad incumbent
Description

Established biopharma with a long history in engineered cytokine (PEGylated IL-2, bempegaldesleukin) and immuno-oncology development. A broader incumbent reference point in the cytokine engineering field, including the high-profile Phase 3 failure of bempegaldesleukin that informs sector risk.

TypeEmerging player
Description

Clinical-stage biotech developing a portfolio of antibody-based therapeutics including bispecifics that engage immune cells, with mechanistic overlap to Synthekine's immuno-oncology programs (e.g., next-generation immune agonists targeting similar biology).

TypeOthers
Description

Clinical-stage biotech with Probody platform for conditionally activated biologics in oncology. Highly relevant as a proxy because Synthekine CEO Debanjan Ray was previously CFO/head of corporate development at CytomX, and the company shares investor syndicate overlap (Canaan, Samsara).

TypeDirect peer
Description

Predecessor-stage company that pioneered de novo protein design for cytokine mimetics (NL-201, a de novo IL-2/IL-15 mimetic) and merged with Medicenna. Important historical comparator for Synthekine's engineered cytokine approach, particularly the surrogate cytokine agonist concept.

TypeOthers
Description

Clinical-stage immunology company developing antibody therapeutics for inflammatory and autoimmune disease. Relevant given the overlap of Synthekine's new Board Chair John Orwin (also AnaptysBio Chair) and shared focus on selective immune modulation in autoimmune disease.

TypeDirect peer
Description

Clinical-stage company developing engineered cytokine variants (IL-2, IL-4, IL-13 Superkines) for oncology and autoimmune disease. Closely comparable to Synthekine's protein-engineered cytokine strategy, including selective agonists designed to address wild-type cytokine pleiotropy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Synthekine

Cytokine Therapeutics / Biopharmaceuticalssynthekine.com

Synthekine is a pre-revenue, clinical-stage biotherapeutics company engineering selective cytokine therapeutics via three platforms — Cytokine Partial Agonists, Orthogonal IL-2, and Surrogate Cytokine Agonists — for oncology and autoimmune diseases, with lead asset STK-012 in Phase 2 for NSCLC.

What Synthekine does

Synthekine is a private, clinical-stage biotherapeutics company founded in 2018 and headquartered in Menlo Park, California, that engineers next-generation cytokine therapeutics for oncology and autoimmune/inflammatory diseases. The company deploys three proprietary cytokine engineering platforms: Cytokine Partial Agonists (which tune receptor binding to decouple efficacy from toxicity), Orthogonal IL-2 (orthoIL-2) Technology (which creates engineered ligand-receptor pairs independent of the endogenous cytokine system to enable controlled in vivo expansion of cell therapies), and Surrogate Cytokine Agonists (SCAs) (which dimerize or multimerize receptor subunits in non-natural configurations to create novel cell selectivity). The lead clinical asset STK-012, an α/β-biased IL-2 partial agonist, is in a global randomized Phase 2 trial (SYNERGY-101) in first-line PD-L1 negative nonsquamous NSCLC and has generated a 50% Phase 1b response rate versus 23-32% for standard treatments; SYNCAR-001 combined with STK-009 (orthogonal IL-2 plus CD19 CAR-T) received FDA Fast Track Designation for lupus without lymphodepletion.

Synthekine operates as a pre-revenue clinical-stage biotech with no commercialized products and derives its capital base from equity financings — $82M Series A (2020), $107.5M Series B (2021), and $100M Series C (2023), totaling approximately $313M from investors including Canaan Partners, Samsara BioCapital, The Column Group, Deerfield Management, and Janus Henderson Investors. The go-to-market model combines internal pipeline development with strategic pharma collaborations: a 2021 worldwide research and licensing agreement with Merck leveraging the SCA platform, a January 2024 strategic collaboration with Sanofi on selective IL-10 receptor agonists for inflammatory disease, and a February 2026 clinical trial collaboration with Merck to evaluate STK-012 plus Keytruda in the SYNERGY-101 study. Future revenue mechanics depend on partnership upfronts, milestone payments, and royalties rather than direct sales.

The company serves patients in oncology (solid tumors including NSCLC, hepatocellular carcinoma; CD19+ hematologic malignancies) and autoimmune/inflammatory disease (systemic lupus erythematosus and related conditions), with scientific leadership grounded in founder K. Christopher Garcia's Stanford structural biology research, CMO Naiyer Rizvi's checkpoint immunotherapy track record, and a board that includes the scientific leads behind ipilimumab and nivolumab discovery. Synthekine retains worldwide rights to its core programs and employs 51-100 people across its single Menlo Park headquarters.

Synthekine firmographics

Firmographics
Name
Synthekine
Legal name
Synthekine, Inc.
Website
https://synthekine.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
Synthekine is a pre-revenue, clinical-stage biotherapeutics company engineering selective cytokine therapeutics via three platforms — Cytokine Partial Agonists, Orthogonal IL-2, and Surrogate Cytokine Agonists — for oncology and autoimmune diseases, with lead asset STK-012 in Phase 2 for NSCLC.
Ownership category
akta.pro rank

Synthekine industry classification

Industry
Product category
Cytokine Therapeutics / Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Engineered cytokine therapeutics
  • Cytokine partial agonists
  • Orthogonal IL-2 therapeutics
  • Immuno-oncology biopharmaceuticals
  • CAR-T combination therapies

Where Synthekine is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Synthekine business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Revenue: Pre-revenue clinical stage biotech company. Revenue expected from commercialization of cytokine therapeutic pipeline including STK-012 (Phase 2), STK-026 (IND enabling), and cell therapy programs. Partnerships with Merck and Sanofi provide upfront payments and potential milestone payments plus royalties.
  2. Strategic Collaboration Payments: Collaboration agreements with pharmaceutical partners generate upfront payments, research funding, development milestones, and commercial royalties. Examples include Sanofi IL-10 collaboration and Merck surrogate cytokine agonist platform partnership.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Synthekine product offering

Product offering

Core offering

Synthekine discovers, develops and plans to commercialize engineered cytokine therapeutic candidates for cancer and autoimmune, inflammatory, and metabolic diseases. Its lead clinical programs include STK-012 (IL-2 partial agonist in Phase 2 for non-small cell lung cancer), STK-009 + SYNCAR-001 (orthogonal IL-2 paired with CD19 CAR-T, FDA Fast Track designated for lupus), and STK-026 (IL-12 partial agonist). The company monetizes its pipeline through a mix of internal development, co-development partnerships (Merck, Sanofi) and milestone/royalty-bearing licensing agreements.

Differentiator

Problem solved

Functional benefit

Products and services

  • STK-012 STK-012 is an α/β-biased IL-2 partial agonist designed to preferentially stimulate tumor-killing T cells while avoiding toxicity from NK cells and naïve T cells. It is in Phase 2 (SYNERGY-101) for first-line PD-L1 negative non-squamous NSCLC, with Phase 1b data showing a 50% response rate vs. 23-32% with standard treatments in this population.
  • STK-009 + SYNCAR-001 (CD19 CAR-T combination) Combination of STK-009, an orthogonal IL-2 ligand, with SYNCAR-001, a CD19 CAR-T cell therapy engineered to express the orthogonal IL-2 receptor. Designed to deliver highly selective proliferation and activation in vivo, removing the need for lymphodepletion and increasing durability and potency of adoptive cell therapies. Indication targets include CD19+ hematologic malignancies and lupus.
  • STK-026 STK-026 is a detoxified IL-12 partial agonist designed to sustain CD8+ T cell activity while reducing NK-mediated cytokine release and toxicities associated with wild-type IL-12. Program is in IND-enabling development.
  • Selective IL-10 receptor agonist program (Sanofi collaboration) Selective IL-10 receptor agonists developed through Synthekine's cytokine partial agonist platform for the treatment of inflammatory and autoimmune diseases. Licensed to Sanofi under a strategic collaboration; Synthekine performs research through preclinical stage, after which Sanofi assumes preclinical, clinical, and commercial responsibility.
  • Surrogate Cytokine Agonists (SCA) platform program (Merck collaboration) Surrogate Cytokine Agonists developed using Synthekine's SCA platform, which dimerizes or multimerizes cytokine receptor subunits in ways wild-type cytokines cannot, enabling non-natural receptor pairing. Licensed to Merck for up to two cytokine targets, with Synthekine performing initial research and Merck holding exclusive development, manufacturing and commercialization rights.

Quantifiable outcome

  • 50% response rate with STK-012 in PD-L1 negative NSCLC vs 23-32% with standard treatments
  • +1 more outcomes

Companies that use Synthekine

Customer profile

Segments2 records

Ideal customer profiles2 records

Synthekine technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Synthekine partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and flagship.

  • Merck (MSD)coreStrategic or Co-development Partner · 26 February 2026Clinical trial collaboration and supply agreement to evaluate STK-012 in combination with Keytruda (pembrolizumab) and chemotherapy in the SYNERGY-101 randomized Phase 2 study for first-line PD-L1 negative nonsquamous NSCLC. Merck supplies Keytruda for the combination regimen. Both companies retain commercial rights to their respective compounds as monotherapies or in combination regimens.
  • SanoficoreStrategic or Co-development Partner · 25 January 2024Strategic collaboration to develop and commercialize selective IL-10 receptor agonists for the treatment of inflammatory diseases. Collaboration focuses on advancing Synthekine's multiple approaches to optimizing IL-10. Synthekine and Sanofi collaborate on research activities up to a defined point of preclinical development, after which Sanofi assumes responsibility for preclinical, clinical, and commercial activities.
  • Merck (MSD)flagshipStrategic or Co-development Partner · 1 November 2021Worldwide research collaboration and licensing agreement leveraging Synthekine's proprietary surrogate cytokine agonist platform to discover, develop and commercialize novel cytokine therapeutics. Synthekine responsible for initial research efforts in collaboration with Merck, and Merck has exclusive rights to develop, manufacture and commercialize surrogate cytokine agonists for up to two cytokine targets.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Synthekine competitors and assessment

Company assessment

Direct peers

  • Xilio Therapeutics: Clinical-stage biotech with tumor-activated immunotherapies including engineered cytokines and immune cell engagers. Competes in the same immuno-oncology and cytokine-engineering space as Synthekine, with a focus on selective activation in the tumor microenvironment.
  • Werewolf Therapeutics: Clinical-stage biotech developing PREDATOR platform-engineered cytokine therapeutics (INDUKINEs) for oncology. Most direct comparable to Synthekine's engineered-cytokine approach and selective IL-2/IL-12 partial agonism, with multiple programs in clinical development for solid tumors.
  • Neoleukin Therapeutics: Predecessor-stage company that pioneered de novo protein design for cytokine mimetics (NL-201, a de novo IL-2/IL-15 mimetic) and merged with Medicenna. Important historical comparator for Synthekine's engineered cytokine approach, particularly the surrogate cytokine agonist concept.
  • Medicenna Therapeutics: Clinical-stage company developing engineered cytokine variants (IL-2, IL-4, IL-13 Superkines) for oncology and autoimmune disease. Closely comparable to Synthekine's protein-engineered cytokine strategy, including selective agonists designed to address wild-type cytokine pleiotropy.

Emerging players

  • Allogene Therapeutics: Clinical-stage allogeneic CAR-T developer with a broad pipeline of off-the-shelf cell therapies. Comparable to Synthekine's SYNCAR-001 + STK-009 CAR-T + orthogonal IL-2 program as it advances into autoimmune indications like lupus without lymphodepletion.
  • Cugene: Clinical-stage biotech developing engineered IL-2 and IL-15 cytokine variants (e.g., CUG252) for autoimmune disease. Directly comparable to Synthekine's engineered cytokine efforts in inflammation/autoimmune indications.
  • Compass Therapeutics: Clinical-stage biotech developing a portfolio of antibody-based therapeutics including bispecifics that engage immune cells, with mechanistic overlap to Synthekine's immuno-oncology programs (e.g., next-generation immune agonists targeting similar biology).

Broad incumbents

  • Nektar Therapeutics: Established biopharma with a long history in engineered cytokine (PEGylated IL-2, bempegaldesleukin) and immuno-oncology development. A broader incumbent reference point in the cytokine engineering field, including the high-profile Phase 3 failure of bempegaldesleukin that informs sector risk.

Others

  • CytomX Therapeutics: Clinical-stage biotech with Probody platform for conditionally activated biologics in oncology. Highly relevant as a proxy because Synthekine CEO Debanjan Ray was previously CFO/head of corporate development at CytomX, and the company shares investor syndicate overlap (Canaan, Samsara).
  • AnaptysBio: Clinical-stage immunology company developing antibody therapeutics for inflammatory and autoimmune disease. Relevant given the overlap of Synthekine's new Board Chair John Orwin (also AnaptysBio Chair) and shared focus on selective immune modulation in autoimmune disease.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Synthekine social profiles

Digital presence

Synthekine financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Synthekine leadership team

Management profile

Number of profiles

Profiles12 records

Synthekine funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Synthekine M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synthekine

What does Synthekine do?

Synthekine discovers, develops and plans to commercialize engineered cytokine therapeutic candidates for cancer and autoimmune, inflammatory, and metabolic diseases. Its lead clinical programs include STK-012 (IL-2 partial agonist in Phase 2 for non-small cell lung cancer), STK-009 + SYNCAR-001 (orthogonal IL-2 paired with CD19 CAR-T, FDA Fast Track designated for lupus), and STK-026 (IL-12 partial agonist). The company monetizes its pipeline through a mix of internal development, co-development partnerships (Merck, Sanofi) and milestone/royalty-bearing licensing agreements.

Is Synthekine a public or private company?

Synthekine is a private company. It is classified as venture growth investor backed and is currently operating.

When was Synthekine founded?

Synthekine was founded in 2019. It employs 51 to 100 people.

Where is Synthekine based?

Synthekine is headquartered in Menlo Park, United States, in the North America region.

How does Synthekine make money?

Two revenue lines are on record. Pharmaceutical Product Revenue is the primary driver. The others are strategic Collaboration Payments.

Who are Synthekine's main competitors?

Direct peers on record are Xilio Therapeutics, Werewolf Therapeutics, Neoleukin Therapeutics and Medicenna Therapeutics. Emerging players are Allogene Therapeutics, Cugene and Compass Therapeutics. Nektar Therapeutics is listed as a broad incumbent. Others are CytomX Therapeutics and AnaptysBio.

Does Synthekine have an API?

No public API is recorded for Synthekine.

What industry is Synthekine in?

Synthekine's product category is Cytokine Therapeutics / Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins, with a secondary code of HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MorningstarSynthekine Appoints Veteran Biotech Leader Susan M. Molineaux, Ph.D. as Chief Executive OfficerSynthekine appointed Susan M. Molineaux, Ph.D., as CEO, succeeding Debanjan Ray, who will remain an advisor. Molineaux brings over 20 years of biotech leadership, including roles at Para Therapeutics and Calithera Biosciences. The company continues advancing STK-012 into late-stage clinical development for NSCLC.Business Wire BlogSynthekine Appoints Veteran Biotech Leader Susan M. Molineaux, Ph.D. as Chief Executive OfficerSynthekine appointed Susan M. Molineaux, Ph.D., as CEO, succeeding Debanjan Ray, who will remain as advisor. Molineaux brings over 20 years of biotech leadership, including roles at Para Therapeutics and Calithera Biosciences. The company continues advancing STK-012 into late-stage clinical development for NSCLC.BioSpaceBiotech leaders pitch Pazdur as next FDA chiefOver 100 biotech executives sent a letter to President Donald Trump recommending former FDA regulator Richard Pazdur to lead the agency following the resignation of Commissioner Marty Makary, describing a period of crisis at the FDA marked by staff exodus, missed deadlines, and eroding scientific predictability. The executives, including CEOs from companies like ReCode Therapeutics, Ultragenyx, and Synthekine as well as investors from Deerfield Management and RA Capital Management, argue Pazdur's track record of streamlining cancer drug approvals makes him uniquely qualified to restore confidence. Several companies including Capricor Therapeutics, uniQure, and Replimune experienced sudden guidance reversals and drug approval delays under Makary's tenure.BioSpaceSynthekine Presents Updated Clinical and Translational Data Demonstrating Strong Activity for STK‑012 in First‑Line Non‑Squamous NSCLC in Oral Presentation at AACR 2026Synthekine presented updated data for STK-012 plus pembrolizumab and chemotherapy in first-line PD-L1-negative non-squamous NSCLC, showing a 50% objective response rate in 36 efficacy-evaluable patients. In the STK11/KEAP1 co-mutated subgroup, the regimen achieved a 50% ORR, 5.5-month median PFS, and 88% 6-month overall survival. The company is enrolling patients in the SYNERGY-101 Phase 2 trial.Business Wire BlogSynthekine Presents Updated Clinical and Translational Data Demonstrating Strong Activity for STK‑012 in First‑Line Non‑Squamous NSCLC in Oral Presentation at AACR 2026Synthekine presented updated data for STK-012 plus pembrolizumab and chemotherapy in first-line PD-L1-negative non-squamous NSCLC at AACR 2026. The regimen achieved a 50% objective response rate in the overall population and 61% in patients with STK11/KEAP1/SMARCA4 alterations, with 88% 6-month overall survival in the STK11/KEAP1 co-mutated subgroup.BioSpaceSynthekine Announces AACR 2026 Oral Presentation of Updated Phase 1a/1b Clinical and Translational Data for STK‑012 in First‑Line Nonsquamous NSCLC with Features of Immunotherapy ResistanceSynthekine Inc. announced that updated clinical and translational data from its Phase 1a/1b trial of STK-012, an α/β biased IL-2 partial agonist, will be presented at the AACR Annual Meeting 2026 in San Diego. The drug is being evaluated in combination with pembrolizumab and chemotherapy for first-line nonsquamous NSCLC patients with features of immune resistance, including PD-L1 negative histology and STK11/KEAP1 mutations, a population representing 40% or more of newly diagnosed patients. Synthekine noted that the SYNERGY-101 global, randomized Phase 2 trial is currently enrolling patients.MorningstarSynthekine Announces AACR 2026 Oral Presentation of Updated Phase 1a/1b Clinical and Translational Data for STK‑012 in First‑Line Nonsquamous NSCLC with Features of Immunotherapy ResistanceSynthekine Inc. announced updated Phase 1a/1b clinical and translational data for its STK-012 α/β biased IL-2 partial agonist will be presented at the AACR Annual Meeting 2026 in San Diego. The trial evaluates STK-012 in combination with pembrolizumab and chemotherapy for first-line nonsquamous NSCLC patients with immunotherapy resistance features, including PD-L1 negative histology and STK11/KEAP1 mutations. The SYNERGY-101 Phase 2 trial is currently enrolling globally, with the company noting that 40% or more of newly diagnosed NSQ NSCLC patients have immune resistance features.Clinical Trials ArenaSynthekine and MSD collaborate for STK-012 combination trial to treat NSCLCSynthekine has entered a clinical trial partnership and supply agreement with MSD (Merck) to investigate its novel immunotherapy candidate STK-012 combined with Keytruda and chemotherapy in the SYNERGY-101 Phase II trial for first-line PD-L1 negative nonsquamous non-small cell lung cancer. The global, randomized trial began enrolling patients in November 2025 with the first patient already dosed, aiming to compare the STK-012 combination against standard pembrolizumab plus chemotherapy. Both companies retain all commercial rights to their respective compounds for use in combination regimens or as monotherapies.BioSpaceSynthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1Synthekine Inc. announced a clinical trial collaboration and supply agreement with Merck to evaluate STK-012, its first-in-class IL-2 receptor biased partial agonist, in combination with Keytruda (pembrolizumab) and chemotherapy in the ongoing SYNERGY-101 randomized Phase 2 study for first-line PD-L1 negative nonsquamous non-small cell lung cancer. Under the agreement, Merck will supply Keytruda for the combination regimen, while Phase 1b data showed a 50% response rate in this patient population. Both companies will retain commercial rights to their respective compounds as monotherapies or in combination regimens.Business Wire BlogSynthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1Synthekine Inc. announced a clinical trial collaboration and supply agreement with Merck to evaluate its drug candidate STK-012 in combination with Keytruda and chemotherapy in the ongoing SYNERGY-101 randomized Phase 2 study for first-line PD-L1 negative nonsquamous non-small cell lung cancer. Under the terms of the agreement, Merck will supply Keytruda while both companies retain commercial rights to their respective compounds. The first patient was dosed in November 2025, and the study aims to demonstrate improved clinical outcomes for patients who receive limited benefit from current standard of care therapies.